Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.

The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:

breast cancer
cancer cell signaling
cancer epidemiology and prevention
cancer genetics
cancer imaging and image-directed interventions
cancer immunity and immunotherapy
cancer metabolism
cancer molecular targets and therapeutics
cardio-oncology
gastrointestinal cancers
genitourinary oncology
gynecological oncology
head and neck cancer
hematologic malignancies
molecular and cellular oncology
neuro-oncology and neurosurgical oncology
pediatric oncology
pharmacology of anti-cancer drugs
radiation oncology
skin cancer
surgical oncology
thoracic oncology.

In particular, the journal welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.

Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:

independent clinical or patient cohorts that are not publicly available
biological validation of the main conclusions, either in vitro or in vivo
multi-database queries (bibliometric studies only)

Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the Frontiers Standards for research methodology policy, for more information.

Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.

Impact

Frontiers in Oncology

Cancer Cell Signaling